Biogen Inc. research and ratings by Barron's. View BIIB revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Private Advisor Group LLC trimmed its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 38.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange ...

Savant Capital LLC raised its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 11.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 4,179 shares of the biotechnology ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of $22 ...

We recently compiled a list of the 12 Cheap Healthcare Stocks to Buy Heading into 2025. In this article, we are going to take a look at where Biogen Inc.

Its key products include Avonex, Plegridy, Tysabri, and Tecfidera for multiple sclerosis; Spinraza for spinal muscular atrophy; Fumaderm for severe plaque psoriasis; and Fampyra for MS symptom ...

Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Biogen (BIIB – Research Report). The associated price target remains the same with $300.00. Andrew Fein has given his ...

Polpharma was, therefore, not entitled to use Tecfidera as a reference medicinal product for its generic version of diethyl fumarate (DMF), even though any regulatory data protection for Fumaderm ...

The following are today's upgrades for Validea's Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have low P/B and P/E ...